Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies

Jutta Stoffers-Winterling*, Ole Jakob Storebø, Klaus Lieb

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

86 Downloads (Pure)

Abstrakt

Purpose of the Review: We aim to identify the most recent evidence of randomised controlled trials evaluating continued drug treatments in people with a diagnosis of BPD, review the most recent findings, highlight trends in terms of currently ongoing studies and comment on the overall body of evidence. Recent Findings: We identified seven new RCTs, plus newly available data for an older RCT. Only three of these RCTs have been published in full text, while we found study data posted at trial registry platforms for the others. Summary: The new findings do not support fluoxetine as a treatment option for suicide and self-harm prevention. A large effectiveness study did not detect beneficial effects of lamotrigine in routine care. The prevalent use of medications in BPD is still not reflected or supported by the current evidence. More research is needed regarding the most commonly used substances and substance classes, i.e. SSRIs, and quetiapine, but also with respect to people presenting with distinct comorbid conditions.

OriginalsprogEngelsk
Artikelnummer37
TidsskriftCurrent Psychiatry Reports
Vol/bind22
Udgave nummer8
Antal sider10
ISSN1523-3812
DOI
StatusUdgivet - 1. aug. 2020

Fingeraftryk

Dyk ned i forskningsemnerne om 'Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies'. Sammen danner de et unikt fingeraftryk.

Citationsformater